On Dec. 14, 2020, Moderna confirmed that the Company had concluded an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support ongoing efforts to secure access to a safe and effective COVID-19 vaccine for the people of Singapore.

The data from the Phase 3 COVE study involving 30,000 participants demonstrated efficacy of 94.1% against COVID-19 and 100% against severe COVID-19.  Moderna announced data showing that mRNA-1273 remains stable at 2ﾰ to 8ﾰC (36ﾰ to 46ﾰF), the temperature of a standard home or medical refrigerator, for 30 days.